Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Scarpi

Showing results (151-160 of 215) with videos related to

Pageof 22
Sort By:
The Oncologist|January 4, 2024
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II TrialFrancesco Schettini, Michela Palleschi, Francesca Mannozzi, et al.
JCO Precision Oncology|February 1, 2022
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA AnalysisVincenza Conteduca, Emanuela Scarpi, Federica Matteucci, et al.
BMC Medicine|February 1, 2022
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxelGiorgia Gurioli, Vincenza Conteduca, Nicole Brighi, et al.
Clinical & Developmental Immunology|October 12, 2010
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysisLaura Ridolfi, Massimiliano Petrini, Laura Fiammenghi, et al.
Scientific Reports|September 7, 2017
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trialAlessandro Passardi, Emanuela Scarpi, Fabio Gelsomino, et al.
Translational Oncology|June 12, 2018
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?Giuseppe Bronte, Sara Bravaccini, Sara Ravaioli, et al.
Oncotarget|April 28, 2016
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactionsAndrea Casadei Gardini, Elena Tenti, Carla Masini, et al.
Biomolecules|August 27, 2021
Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 StudiesAlessandro Passardi, Ilario Giovanni Rapposelli, Emanuela Scarpi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 10, 2018
An aggressive early gastric cancer: Kodama's PenA typePaolo Morgagni, Leonardo Solaini, Luca Saragoni, et al.
Heart (British Cardiac Society)|January 26, 2013
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factorsAlberto Farolfi, Elisabetta Melegari, Michele Aquilina, et al.
Pageof 22

Showing results (151-160 of 215) with videos related to

Sort By:
Pageof 22
The Oncologist|January 4, 2024
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II TrialFrancesco Schettini, Michela Palleschi, Francesca Mannozzi, et al.
JCO Precision Oncology|February 1, 2022
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA AnalysisVincenza Conteduca, Emanuela Scarpi, Federica Matteucci, et al.
BMC Medicine|February 1, 2022
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxelGiorgia Gurioli, Vincenza Conteduca, Nicole Brighi, et al.
Clinical & Developmental Immunology|October 12, 2010
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysisLaura Ridolfi, Massimiliano Petrini, Laura Fiammenghi, et al.
Scientific Reports|September 7, 2017
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trialAlessandro Passardi, Emanuela Scarpi, Fabio Gelsomino, et al.
Translational Oncology|June 12, 2018
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?Giuseppe Bronte, Sara Bravaccini, Sara Ravaioli, et al.
Oncotarget|April 28, 2016
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactionsAndrea Casadei Gardini, Elena Tenti, Carla Masini, et al.
Biomolecules|August 27, 2021
Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 StudiesAlessandro Passardi, Ilario Giovanni Rapposelli, Emanuela Scarpi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 10, 2018
An aggressive early gastric cancer: Kodama's PenA typePaolo Morgagni, Leonardo Solaini, Luca Saragoni, et al.
Heart (British Cardiac Society)|January 26, 2013
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factorsAlberto Farolfi, Elisabetta Melegari, Michele Aquilina, et al.
Pageof 22